Hemp extract for treatment of pain in animals
The present disclosure relates to methods of treating pain in veterinary subjects using pharmaceutical compositions and dosage forms comprising hemp extract.
1. A pharmaceutical composition comprising hemp extract and a carrier, wherein the hemp extract comprises:
cannabidiol;
cannabidiolic acid;
cannabigerolic acid; and
D9-tetrahydrocannabinol,
wherein the cannabidiol and the cannabidiolic acid are present in the pharmaceutical composition at a first ratio, and the D9-tetrahydrocannabinol and total cannabinoids are present in the pharmaceutical composition at a second ratio, wherein the first ratio is from about 0.6:1 to about 1:0.6, and wherein the second ratio is from about 1:50 to about 1:20.
2. The pharmaceutical composition of claim 1 , wherein the hemp extract further comprises cannabichromene.
3. The pharmaceutical composition of claim 1 , wherein the hemp extract further comprises four or more of the following:
α-pinene;
β-myrcene;
β-pinene;
δ-limonene;
linalool
β-caryophyllene;
α-humulene;
nerolidol 2;
guaiol;
caryophyllene oxide; and
α-bisabolol.
4. The pharmaceutical composition of claim 1 , wherein the concentration of D9-tetrahydrocannabinol is less than about 2 mg/mL.
5. The pharmaceutical composition of claim 1 , wherein the concentration of D9-tetrahydrocannabinol is less than about 1.5 mg/mL.
6. The pharmaceutical composition of claim 1 , wherein the concentration of D9-tetrahydrocannabinol is less than about 1.0 mg/mL.
7. The pharmaceutical composition of claim 3 , wherein the hemp extract further comprises one or more of:
camphene;
β-ocimene;
eucalyptol;
isopulegol; and/or
nerolidol 1.
8. A pharmaceutical composition for oral delivery comprising hemp extract and a carrier, wherein the hemp extract comprises:
cannabidiol;
cannabidiolic acid; and
D9-tetrahydrocannabinol,
wherein the cannabidiol and the cannabidiolic acid are present in the pharmaceutical composition at a first ratio, and the D9-tetrahydrocannabinol and total cannabinoids are present in the pharmaceutical composition at a second ratio, wherein the first ratio is from about 0.6:1 to about 1:0.6, wherein the second ratio is from about 1:50 to about 1:20, and wherein the carrier is selected from the group consisting of linseed oil, olive oil, fish oil, salmon oil, coconut oil, catnip oil, sesame oil, and grapeseed oil.
9. The pharmaceutical composition of claim 8 , wherein the hemp extract further comprises cannabigerolic acid and cannabichromene.
10. The pharmaceutical composition of claim 8 , wherein the hemp extract further comprises four or more of the following:
α-pinene;
β-myrcene;
β-pinene;
δ-limonene;
linalool;
β-caryophyllene;
α-humulene;
nerolidol 2;
guaiol;
caryophyllene oxide; and
α-bisabolol.
11. The pharmaceutical composition of claim 8 , wherein the concentration of D9-tetrahydrocannabinol is less than about 2 mg/mL.
12. The pharmaceutical composition of claim 8 , wherein the concentration of D9-tetrahydrocannabinol is less than about 1.5 mg/mL.
13. The pharmaceutical composition of claim 8 , wherein the concentration of D9-tetrahydrocannabinol is less than about 1.0 mg/mL.
14. The pharmaceutical composition of claim 10 , wherein the hemp extract further comprises one or more of:
camphene;
β-ocimene;
eucalyptol;
isopulegol; and/or
nerolidol 1.
15. The pharmaceutical composition of claim 8 , wherein the carrier is grapeseed oil.
16. The pharmaceutical composition of claim 8 , wherein the carrier is catnip oil.
17. A pharmaceutical composition formulated as a chew comprising hemp extract and a carrier, wherein the hemp extract comprises:
cannabidiol;
cannabidiolic acid; and
D9-tetrahydrocannabinol,
wherein the cannabidiol and the cannabidiolic acid are present in the pharmaceutical composition at a first ratio, and the D9-tetrahydrocannabinol and total cannabinoids are present in the pharmaceutical composition at a second ratio, wherein the first is from about 0.6:1 to about 1:0.6, and wherein the second ratio is from about 1:50 to about 1:20.
18. The pharmaceutical composition of claim 17 , wherein the hemp extract further comprises cannabigerolic acid and cannabichromene.
19. The pharmaceutical composition of claim 17 , wherein the hemp extract further comprises four or more of the following:
α-pinene;
β-myrcene;
β-pinene;
δ-limonene;
linalool;
β-caryophyllene;
α-humulene;
nerolidol 2;
guaiol;
caryophyllene oxide; and
α-bisabolol.
20. The pharmaceutical composition of claim 17 , wherein the concentration of D9-tetrahydrocannabinol is less than about 2 mg/mL.
21. The pharmaceutical composition of claim 17 , wherein the concentration of D9-tetrahydrocannabinol is less than about 1.5 mg/mL.
22. The pharmaceutical composition of claim 17 , wherein the concentration of D9-tetrahydrocannabinol is less than about 1.0 mg/mL.
23. The pharmaceutical composition of claim 17 , wherein the hemp extract further comprises one or more of:
camphene;
β-ocimene;
eucalyptol;
isopulegol; and/or
nerolidol 1.
24. The pharmaceutical composition of claim 17 , wherein the weight of the chew is about 0.5-10 g.